CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) (the "Company"), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the closing of its previously announced initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the "Offering"). In addition, the Company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the Offering, solely to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions. All of the shares are being offered by the Company. The shares began trading on August 13, 2024 on the Nasdaq Global Market under the symbol "ACTU." Titan Partners Group, a division of American Capital Partners, acted as Sole Bookrunner for the Offering. Newbridge Securities Corporation acted as Co-Manager. A registration statement on Form S-1 (the "Registration Statement") relating to these securities was filed with the Securities and Exchange Commission (the "SEC") and was declared effective on August 12, 2024. The Offering was made only by means of a prospectus, forming part of the effective registration statement. A copy of the final prospectus related to ...